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Background: CDC25C, belonging to the Cdc25 phosphatase family, plays a major role 
in cell cycle control, impacting on DNA repair and apoptosis. It has been shown that 
poor prognosis/copy number high Luminal A breast cancers (BCs) are enriched for the 
Aurora kinase pathway including CDC25C leading to CDK1 activation (Ciriello et al, 
Breast Cancer Research Treatment, 2013:409). This study examined the associations of 
CDC25C with clinicopathological and molecular features in BCs including the low grade 
ER positive cohort. 
Methodology: CDC25C mRNA expression was studied in the METABRIC BC cohort 
(n=1980) and externally validated using online expression datasets [bc-GenExMiner 
v4.0]. CDC25C protein expression level was assessed immunohistochemically on a 
large annotated series of BC (n= 1330) and correlations made with clinicopathological 
parameters and patient outcome. 
Results: High CDC25C expression was significantly associated with poor prognostic 
factors including high grade, large tumour size, medullary like tumours, poorer NPI, 
ER-/PR- Her2+ status (p<0.001) and was differentially expressed in poor prognosis 
integrative clusters 5 and 10 (p<0.001). Cytoplasmic CDC25C (c-CDC25C) protein 
showed positive association with non-NST and non-medullary tumour subtypes while 
nuclear CDC25C (n-CDC25C) negatively associated with tumour stage (p<0.05). There 
was no association with ER, PR status, NPI and lymph nodes. However, high c-CDC25C 
resulted in poor survival at 20 years in the Grade 1 ER+ cohort (p=0.007), while high 
n-CDC25C showed better long term survival (p<0.001). Pooled CDC25C expression data 
in the external validation cohort showed an association with poor outcome (p<0.0001, 
HR = 1.45, 95 % CI 1.28—1.64). 
Conclusion: CDC25C appears to be associated with poor prognosis in BC including the 
Grade 1 ER+ cohort, indicating the importance of further functional analyses. 
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